We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Thuramed Tetras Asynchronous Peptide Synthesizer Exceeds Expectations

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Thuramed Tetras Asynchronous Peptide Synthesizer Exceeds Expectations"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

In its second year of commercial sale, the Thuramed Tetras has surpassed even the parent companies, CreoSalus, expectations for sales. ‘The Tetras has been an exceptional success story for CreoSalus’ says CreoSalus representative Brian Boston.

‘Our goal was to introduce the first real change in SPPS technology in over ten years. Peptide research has advanced tremendously over the last decade, but the instrumentation had not, so we remedied that problem for researchers.’

The company says that the TETRAS allows for up to 106 50-150mg/resin reactions orup to 20 500mg-2g/resin reactions to be performed simultaneously, independently and syntheses can be added and removed by the user without disrupting other reactions.

Individualized reactors and dedicated fluid delivery stations allow for an instrument with no cross contamination and exponentially lower waste. Modular delivery stations can be removed and replaced in seconds allowing more user serviceable items than ever before and nearly no 'down time' waiting on traditional instrument service reps to arrive.

The software is fully networkable with remote operation capabilities, SynStatus™ email updates from the TETRAS to the user and online technical service and diagnostic capabilities.